We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says No to Generic Antidepressant Fluvoxamine as a COVID-19 Treatment
FDA Says No to Generic Antidepressant Fluvoxamine as a COVID-19 Treatment
The FDA gave the generic antidepressant fluvoxamine a decisive thumbs-down as a treatment option for COVID-19 this week, only days after an influential independent nonprofit research panel recommended it.